Insider Stock Trading History of Gionco David


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Gionco David since year 2005. The trader's CIK number is 1456864. At the time of this reporting, Gionco David is the Chief Accounting Officer of Stemline Therapeutics Inc . (stock ticker symbol STML). See this page for all insider trading activities at Stemline Therapeutics Inc .

Note that in the past Gionco David also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Gionco David since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2017-03-07 STML Stemline Therapeutics Inc Sale 1,116 8.13 9,073
2017-02-27 STML Stemline Therapeutics Inc Sale 3,500 6.97 24,395
2017-02-28 STML Stemline Therapeutics Inc Sale 2,986 7.01 20,931
2017-01-19 STML Stemline Therapeutics Inc Sale 3,593 11.46 41,175
2016-03-08 STML Stemline Therapeutics Inc Sale 1,148 5.32 6,107
2016-01-19 STML Stemline Therapeutics Inc Sale 3,171 4.82 15,284
2016-01-20 STML Stemline Therapeutics Inc Sale 46 4.69 215
2015-01-20 STML Stemline Therapeutics Inc Sale 3,311 14.22 47,082
2013-10-15 SVNT Savient Pharmaceuticals Inc Sale 47,876 .08 3,830
2013-03-06 SVNT Savient Pharmaceuticals Inc Sale 1,560 .93 1,450
2011-01-24 SVNT Savient Pharmaceuticals Inc Sale 2,032 10.00 20,320
2010-12-20 SVNT Savient Pharmaceuticals Inc Sale 1,536 11.87 18,232
2010-02-16 SVNT Savient Pharmaceuticals Inc Sale 1,253 13.81 17,300
2010-02-09 SVNT Savient Pharmaceuticals Inc Sale 2,037 12.77 26,002
2009-12-21 SVNT Savient Pharmaceuticals Inc Sale 1,511 12.95 19,561
2009-09-15 SVNT Savient Pharmaceuticals Inc Option Ex 7,500 4.32 32,400
2009-09-14 SVNT Savient Pharmaceuticals Inc Sale 10,887 15.36 167,224
2009-09-15 SVNT Savient Pharmaceuticals Inc Sale 7,500 15.95 119,625

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Gionco David (Chief Accounting Officer of Stemline Therapeutics Inc at the time of this reporting) see the Securities and Exchange Commission (SEC) website.